{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:49:29Z","timestamp":1793245769578,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Beh\u00e7et\u2019s disease (BD) is a recurrent multisystem inflammatory disease. Anti-tumor necrosis factor (TNF) \u03b1 agents have been used to treat patients with intestinal BD with severe disease activity or those who are resistant to conventional treatments; however, the long-term efficacy of anti-TNF\u03b1 agents in intestinal BD remains unclear. In the present study, we investigated the clinical outcomes and predictors of discontinuation of anti-TNF\u03b1 agents in patients with intestinal BD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the medical records of patients with intestinal BD who received first-line anti-TNF\u03b1 agents between January 2009 and June 2020. The primary outcome was the percentage of patients who continued anti-TNF\u03b1 therapy for 48\u00a0weeks. Secondary outcomes included the percentage of patients who achieved marked improvement, complete remission, and mucosal healing, as well as predictors of discontinuation of anti-TNF\u03b1 agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 29 patients were included in the study. Twenty-two (75.9%) patients continued anti-TNF\u03b1 therapy for 48\u00a0weeks. The percentage of patients who achieved marked improvement, complete remission, and mucosal healing at week 48 was 48.3%, 37.9%, and 48.3%, respectively. At week 96, 11 (37.9%) patients achieved marked improvement, complete remission, and mucosal healing. A higher C-reactive protein level (CRP;\u2009\u2265\u20091\u00a0mg\/dL) at baseline was a predictor of discontinuation of anti-TNF\u03b1 agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 48-week continuation rate of anti-TNF\u03b1 agents was 75.9% in bio-na\u00efve patients with intestinal BD. However, a higher baseline CRP level (\u2265\u20091\u00a0mg\/dL) was associated with discontinuation of anti-TNF\u03b1 agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02221-0","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:32:10Z","timestamp":1648513930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and predictor of anti-TNF\u03b1 agents in patients with intestinal Beh\u00e7et's disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Haruka","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiko","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-7792","authenticated-orcid":false,"given":"Makoto","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"2221_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","volume":"4","author":"M Suzuki Kurokawa","year":"2004","unstructured":"Suzuki Kurokawa M, Suzuki N. Behcet\u2019s disease. Clin Exp Med. 2004;4:10\u201320.","journal-title":"Clin Exp Med"},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00054725-200108000-00010","volume":"7","author":"CR Lee","year":"2001","unstructured":"Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Beh\u00e7et\u2019s disease. Inflamm Bowel Dis. 2001;7:243\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"2221_CR4","doi-asserted-by":"publisher","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet\u2019s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine. 2016;95:e3348.","journal-title":"Medicine"},{"key":"2221_CR5","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318.","journal-title":"Ann Rheum Dis"},{"key":"2221_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55:679\u2013700.","journal-title":"J Gastroenterol"},{"key":"2221_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2017.377","volume":"33","author":"YE Park","year":"2018","unstructured":"Park YE, Cheon JH. Updated treatment strategies for intestinal Beh\u00e7et\u2019s disease. Korean J Intern Med. 2018;33:1\u201319.","journal-title":"Korean J Intern Med"},{"key":"2221_CR8","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/MCG.0b013e3182431d56","volume":"46","author":"YS Jung","year":"2012","unstructured":"Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46:e38-45.","journal-title":"J Clin Gastroenterol"},{"key":"2221_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ibd.21757","volume":"18","author":"YS Jung","year":"2011","unstructured":"Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;18:750\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"2221_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10620-012-2351-9","volume":"58","author":"YS Jung","year":"2013","unstructured":"Jung YS, Cheon JH, Park SJ, et al. Clinical course of intestinal Behcet\u2019s disease during the first five years. Dig Dis Sci. 2013;58:496\u2013503.","journal-title":"Dig Dis Sci"},{"key":"2221_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11894-020-00759-1","volume":"22","author":"Y Park","year":"2020","unstructured":"Park Y, Cheon JH. Update on the treatment of Behcet\u2019s disease of the small Bowel with biologic agents. Curr Gastroenterol Rep. 2020;22:24.","journal-title":"Curr Gastroenterol Rep"},{"key":"2221_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5009\/gnl17462","volume":"12","author":"J Park","year":"2018","unstructured":"Park J, Cheon JH. Anti-tumor necrosis factor therapy in intestinal Beh\u00e7et\u2019s disease. Gut Liver. 2018;12:623\u201332.","journal-title":"Gut Liver"},{"key":"2221_CR13","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine. 2016;95:e3863.","journal-title":"Medicine"},{"key":"2221_CR14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:940-948.e943.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2221_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Beh\u00e7et\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15:395\u2013401.","journal-title":"Intest Res"},{"key":"2221_CR16","first-page":"1152","volume":"105","author":"H Behcet","year":"1937","unstructured":"Behcet H. Uber rezidivierende, aphthose durch ein Virus verursachte Geschuwuere am Mund, am Auge und Genitalien. Dermatol Wochenschr. 1937;105:1152\u20137.","journal-title":"Dermatol Wochenschr"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat Genet. 2010;42:703\u20136.","journal-title":"Nat Genet"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et\u2019s disease. Nat Genet. 2010;42:698\u2013702.","journal-title":"Nat Genet"},{"key":"2221_CR19","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/art.37708","volume":"64","author":"S Hou","year":"2012","unstructured":"Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Beh\u00e7et\u2019s disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64:4104\u201313.","journal-title":"Arthritis Rheum"},{"key":"2221_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.8097338","volume":"260","author":"CS Hsieh","year":"1993","unstructured":"Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547\u20139.","journal-title":"Science"},{"key":"2221_CR21","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1073\/pnas.92.16.7307","volume":"92","author":"CM Bacon","year":"1995","unstructured":"Bacon CM, Petricoin EF 3rd, Ortaldo JR, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA. 1995;92:7307\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123\u201332.","journal-title":"Nat Immunol"},{"key":"2221_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"key":"2221_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm. 2002;11:87\u201393.","journal-title":"Mediat Inflamm"},{"key":"2221_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","volume":"139","author":"Y Imamura","year":"2005","unstructured":"Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet\u2019s disease. Clin Exp Immunol. 2005;139:371\u20138.","journal-title":"Clin Exp Immunol"},{"key":"2221_CR26","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932\u20139.","journal-title":"Lancet"},{"key":"2221_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"2221_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"2221_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333 (quiz 591).","journal-title":"Gastroenterology"},{"key":"2221_CR30","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"2221_CR31","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum"},{"key":"2221_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"key":"2221_CR33","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"2221_CR34","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2018.10.024","volume":"51","author":"N Sugimura","year":"2019","unstructured":"Sugimura N, Mizoshita T, Sugiyama T, et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Beh\u00e7et\u2019s disease. Dig Liver Dis. 2019;51:967\u201371.","journal-title":"Dig Liver Dis"},{"key":"2221_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","volume":"62","author":"J Zou","year":"2017","unstructured":"Zou J, Ji DN, Cai JF, et al. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet\u2019s disease treated with infliximab. Dig Dis Sci. 2017;62:441\u20137.","journal-title":"Dig Dis Sci"},{"key":"2221_CR36","first-page":"171","volume":"47","author":"J Zou","year":"2017","unstructured":"Zou J, Ji DN, Shen Y, et al. Mucosal healing at 14 weeks predicts better outcome in low-dose infliximab treatment for Chinese patients with active intestinal Behcet\u2019s disease. Ann Clin Lab Sci. 2017;47:171\u20137.","journal-title":"Ann Clin Lab Sci"},{"key":"2221_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-4362.1986.tb02232.x","volume":"25","author":"AU M\u00fcft\u00fco\u011flu","year":"1986","unstructured":"M\u00fcft\u00fco\u011flu AU, Yazici H, Yurdakul S, et al. Beh\u00e7et\u2019s disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol. 1986;25:235\u20139.","journal-title":"Int J Dermatol"},{"key":"2221_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ijd.12224","volume":"53","author":"M Melikoglu","year":"2014","unstructured":"Melikoglu M, Topkarci Z. Is there a relation between clinical disease activity and acute phase response in Behcet\u2019s disease? Int J Dermatol. 2014;53:250\u20134.","journal-title":"Int J Dermatol"},{"key":"2221_CR39","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"10","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) immunotherapy. Cold Spring Harb Perspect Biol. 2018;10:a028456.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2221_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","volume":"24","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179\u201389.","journal-title":"Immunity"},{"key":"2221_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10:314\u201324.","journal-title":"Nat Immunol"},{"key":"2221_CR42","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","volume":"29","author":"H Ogura","year":"2008","unstructured":"Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008;29:628\u201336.","journal-title":"Immunity"},{"key":"2221_CR43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA"},{"key":"2221_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/ibd.21886","volume":"18","author":"T Hibi","year":"2012","unstructured":"Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn\u2019s disease. Inflamm Bowel Dis. 2012;18:1480\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"2221_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10067-005-0106-0","volume":"25","author":"L Petrovic-Rackov","year":"2006","unstructured":"Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol. 2006;25:448\u201352.","journal-title":"Clin Rheumatol"},{"key":"2221_CR46","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ard.2011.153023","volume":"70","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1208\u201315.","journal-title":"Ann Rheum Dis"},{"key":"2221_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","volume":"2","author":"M Ferrante","year":"2008","unstructured":"Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219\u201325.","journal-title":"J Crohns Colitis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02221-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02221-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02221-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:09:33Z","timestamp":1666598973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02221-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02221-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-915770\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"19 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. This study was approved by the ethics committee of Kobe University Hospital (No. B200279). The requirement for written informed consent to participate in the study was replaced by an opt-out method, owing to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The requirement for written informed consent was replaced by an opt-out method owing to the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}